Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Treasury Shares (2021 - 2025)

Zentalis Pharmaceuticals has reported Treasury Shares over the past 5 years, most recently at $5.4 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 28.56% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.4 million, down 28.56%, while the annual FY2025 figure was $5.4 million, 28.56% down from the prior year.
  • Treasury Shares for Q4 2025 was $5.4 million at Zentalis Pharmaceuticals, down from $7.5 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $7.5 million in Q4 2024 and troughed at $949.0 in Q4 2023.
  • A 5-year average of $2.7 million and a median of $274195.0 in 2021 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: tumbled 99.24% in 2023 and later soared 790205.58% in 2024.
  • Year by year, Treasury Shares stood at $274195.0 in 2021, then plummeted by 54.23% to $125506.0 in 2022, then plummeted by 99.24% to $949.0 in 2023, then soared by 790205.58% to $7.5 million in 2024, then decreased by 28.56% to $5.4 million in 2025.
  • Business Quant data shows Treasury Shares for ZNTL at $5.4 million in Q4 2025, $7.5 million in Q4 2024, and $949.0 in Q4 2023.